FrancophonIA/ELRC3.0 huggingface dataset:
English: Tabulated list of adverse reactions in non-small cell lung cancer for TAXOTERE 75 mg/m² in combination with cisplatin
Estonian: Kõrvaltoimete tabel mitteväikerakk-kopsuvähi kombinatsioonravi korral TAXOTERE-ga annuses 75 mg/m2 ja tsisplatiiniga
English: How to store TAXOTERE Contents of the pack and otherinformation
Estonian: Kuidas TAXOTERE välja näeb ja pakendi sisu
English: Pain
Estonian: PAKEND
English: G3/4 Blood bilirubin increased (< 5%);
Estonian: astme bilirubiinisisalduse tõus veres (< 2%)
English: TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion docetaxel intravenous use
Estonian: TAXOTERE 20 mg/0,5 ml infusioonilahuse kontsentraat Docetaxelum intravenoosne
English: Lymphoedema (G3/4:
Estonian: Lümfiturse (3./4.
English: What TAXOTERE looks like and contents of the pack TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion is a clear viscous, yellow to brownyellow solution.
Estonian: TAXOTERE 20 mg/0,5 ml infusioonilahuse kontsentraat on läbipaistev viskoosne kollane kuni pruunikaskollane lahus.
English: This medicinal product contains 13 % (w/w) ethanol 95% v/v (alcohol), i.e. up to 252 mg ethanol 95% v/v per solvent vial, equivalent to 6 ml of beer or 2.6 ml wine.
Estonian: See ravim sisaldab kaaluliselt 13% etanooli (alkoholi) mahukangusega 95%, st kuni 252 mg 95% etanooli lahusti viaalis, mis vastab 6 ml õllele või 2,6 ml veinile.
English: • Induction chemotherapy followed by chemoradiotherapy (TAX324) The safety and efficacy of docetaxel in the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a randomised, multi-centre open-label, phase III study (TAX324).
Estonian: • Induktsioonkemoteraapia, millele järgneb kemoradioteraapia (TAX 324) Dotsetakseeli efektiivsust ja ohutust lokaalselt levinud pea ja kaelapiirkonna lamerakk-kartsinoomi (SCCHN) induktsioonravis hinnati III faasi mitmekeskuselises avatud juhuslikustatud uuringus (TAX324).
English: As with all parenteral products, TAXOTERE premix solution and infusion solution should be visually inspected prior to use, solutions containing a precipitate should be discarded.
Estonian: Sarnaselt kõigi teiste parenteraalselt kasutatavate toodetega tuleb TAXOTERE eellahust ja infusioonilahust hinnata visuaalselt enne kasutamist ning setet sisaldavaid lahuseid mitte kasutada.
English: • chest tightness; difficulty in breathing
Estonian: • pigistustunne rinnus, hingamisraskus
English: Overall survival was also significantly longer
Estonian: 1 aasta elulemus oli dotsetakseeli grupis (40%) samuti märgatavalt pikem
English: Stomatitis/mucositis grade 3
Estonian: 3. raskusastme stomatiit/mukosiit
English: • Induction chemotherapy followed by radiotherapy (TAX323) The safety and efficacy of docetaxel in the induction treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) was evaluated in a phase III, multi-centre, open-label, randomised study (TAX323).
Estonian: • Induktsioon kemoteraapia, millele järgneb radioteraapia (TAX 323) Dotsetakseeli efektiivsust ja ohutust pea ja kaelapiirkonna lamerakk-kartsinoomi (SCCHN) induktsioonravis hinnati III faasi mitmekeskuselises avatud juhuslikustatud uuringus (TAX323).
English: For breast and non-small cell lung cancers, premedication consisting of an oral corticosteroid, such as dexamethasone 16 mg per day (e.g. 8 mg BID) for 3 days starting 1 day prior to docetaxel administration, unless contraindicated, can reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions.
Estonian: Rinnanäärme-ja mitteväikerakk-kopsuvähi korral vedeliku retentsiooni esinemist ja raskust ning ülitundlikkusreaktsioonide raskust võib vähendada premedikatsioon suukaudsete kortikosteroididega, nt 16 mg deksametasooni päevas (8 mg 2 korda ööpäevas) kolme päeva jooksul, alustades üks päev enne dotsetakseeli manustamist, juhul kui see ei ole vastunäidustatud.
English: • indigestion
Estonian: • verehüübed
English: Anaemia (G3/4: 9.4%); Febrile neutropenia;
Estonian: aste: 1,6%); Febriilne neutropeenia (3./4.
English: Median overall survival (months) 95% CI
Estonian: Üldise elulemuse mediaan (kuud) 95% CI
English: This medicinal product contains 13% (w/w) ethanol 95% v/v (alcohol), i.e. up to 932 mg ethanol 95% v/v per solvent vial, equivalent to 23 ml of beer or 9.5 ml wine.
Estonian: See ravim sisaldab kaaluliselt 13% etanooli (alkoholi) mahukangusega 95%, st kuni 932 mg 95% etanooli lahusti viaalis, mis vastab 23 ml õllele või 9,5 ml veinile.
English: In GEICAM 9805 study peripheral sensory neuropathy that started during the treatment period persisted into the follow-up period in 10 patients (1.9%) in TAC arm and 4 patients (0.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), peripheral sensory neuropathy was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Estonian: Uuringus GEICAM 9805 algas perifeerne sensoorne neuropaatia raviperioodil ja jätkus jälgimisperioodil, 10 patsiendil (1,9%) TAC ravihaaras ja 4 patsiendil (0,8%) FAC ravihaaras.
English: In these metastatic prostate cancer patients, the median overall survival was significantly longer in docetaxel treatment groups than in the standard of care alone group, with a median overall survival 19 months longer with the addition of docetaxel to standard of care (HR = 0.76, 95% CI = 0.62-0.92, p=0.005).
Estonian: Üldise elulemuse mediaan oli dotsetakseeli lisamisel standardravile 19 kuud pikem (HR = 0,76; 95% CI = 0,62…0,92; p = 0,005).
English: • Then, inject via a single injection (one shot) into a 250 ml infusion bag or bottle containing either 5% glucose solution or sodium chloride 9 mg/ml (0.9%) solution for infusion.
Estonian: - Süstige ühe süstena (ühekorraga) 250 ml infusioonikotti või pudelisse, mis sisaldab kas 5% glükoosilahust või 9 mg/ml (0,9%) naatriumkloriidi infusioonilahust.
English: MedDRA system organ classes Very common adverse reactions
Estonian: Väga sagedased kõrvaltoimed Sagedased kõrvaltoimed
English: The addition of the entire contents of the solvent vial to the contents of the TAXOTERE 20 mg/0.5 ml vial ensures a premix concentration of 10 mg/ml docetaxel.
Estonian: Kogu lahustiviaali sisu lisamine TAXOTERE 20 mg/0,5 ml viaalile tagab eellahuse dotsetakseeli kontsentratsiooniga 10 mg/ml.
English: Lymphoedema
Estonian: Tsisplatiin
English: In combination with cisplatin For patients who are dosed initially at docetaxel 75 mg/m in combination with cisplatin and whose nadir of platelet count during the previous course of therapy is < 25,000 cells/mm
Estonian: Patsientidel, kes said esialgu 75 mg/m2 dotsetakseeli kombinatsioonis tsisplatiiniga ja kelle trombotsüütide madalseis eelmises tsüklis oli < 25000 rakku/mm3 või patsientidel, kellel esines febriilset neutropeeniat või tõsiseid mittehematoloogilisi kõrvaltoimeid, tuleb dotsetakseeli annust järgmistes tsüklites langetada 65 mg/m2-ni. Tsisplatiini annuse muutmise kohta vt vastavat ravimi omaduste kokkuvõtet.
English: Nail disorders (severe: 0.8%)
Estonian: Küünte kahjustus (tõsine: 0,4%);
English: TAXOTERE 160 mg/8 ml concentrate for solution for infusion docetaxel
Estonian: TAXOTERE 160 mg/8 ml infusioonilahuse kontsentraat Docetaxelum
English: Preparation of the intravenous administration
Estonian: Ettevalmistus intravenoosseks manustamiseks Infusioonilahuse valmistamine
English: Patients who have previously experienced a hypersensitivity reaction to paclitaxel may be at risk to develop hypersensitivity reaction to docetaxel,
Estonian: Patsientidel, kellel on olnud ülitundlikkusreaktsioone paklitakseelile, on teatatud ülitundlikkusreaktsioonidest dotsetakseelile.
English: Tabulated list of adverse reactions in breast cancer for TAXOTERE 75 mg/m² in combination with doxorubicin
Estonian: Kõrvaltoimete tabel rinnanäärmevähi kombinatsioonravi korral TAXOTERE-ga annuses 75 mg/m2 ja doksorubitsiiniga
English: TAXOTERE 80 mg/2 ml concentrate for solution for infusion docetaxel intravenous use
Estonian: TAXOTERE 80 mg/2 ml infusioonilahuse kontsentraat Docetaxelum intravenoosne
English: One vial of 4 ml of concentrate contains 80 mg of docetaxel.
Estonian: Üks viaal 1 ml kontsentraadiga sisaldab 80 mg dotsetakseeli.
English: In combination with capecitabine
Estonian: Kombinatsioonravi tsisplatiiniga
English: ANNEX II
Estonian: 2. vanusekategooria
English: Nausea (G3/4: 2.4%);
Estonian: aste: 2,4%);
English: PREPARATION GUIDE FOR USE WITH TAXOTERE 80 mg/2 ml CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR TAXOTERE
Estonian: KASUTUSJUHIS TAXOTERE 80 mg/2 ml INFUSIOONILAHUSE KONTSENTRAAT JA TAXOTERE LAHUSTI
English: PREPARATION GUIDE FOR USE WITH TAXOTERE 20 mg/0.5 ml CONCENTRATE FOR SOLUTION FOR INFUSION AND SOLVENT FOR TAXOTERE
Estonian: KASUTUSJUHIS TAXOTERE 20 mg/0,5 ml INFUSIOONILAHUSE KONTSENTRAAT JA TAXOTERE LAHUSTI
English: Patients on the docetaxel arm received docetaxel (T) 75 mg/m followed by cisplatin (P) 75 mg/m followed by
Estonian: Dotsetakseeli haara patsiendid said 75 mg/m2dotsetakseeli (T), millele järgnes tsisplatiin (P) 75 mg/m2 ja seejärel 5-fluorouratsiil (F) 750 mg/m2 päevas püsiinfusioonina 5 päeva (TPF).
English: Diarrhoea (G3/4: 4%); Nausea (G3/4: 4%);
Estonian: aste: 4%); Kõhukinnisus (3./4.
English: Arrhythmia (G3/4:
Estonian: Artralgia (3./4.
English: Metastatic hormone-sensitive prostate cancer The recommended dose of docetaxel is 75 mg/m every 3 weeks for 6 cycles.
Estonian: Soovitatav dotsetakseeli annus on 75 mg/m2 iga 3 nädala järel, kokku 6 tsüklit.
English: Post-Menopausal
Estonian: • ninaverejooks
English: If TAXOTERE concentrate or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water.
Estonian: Kui TAXOTERE kontsentraat või infusioonilahus peaks sattuma nahale, tuleb see viivitamatult ja hoolikalt maha pesta seebi ja veega.
English: Each ml of concentrate for solution for infusion contains 20 mg docetaxel.
Estonian: Iga ml infusioonilahuse kontsentraati sisaldab 20 mg dotsetakseeltrihüdraati.
English: Description of selected adverse reactions in breast cancer for TAXOTERE 100 mg/m² in combination with trastuzumab
Estonian: Rinnanäärmevähi kõrvaltoimete valikuline kirjeldus TAXOTERE-ga annuses 100 mg/ m² ja trastuzumabiga
English: • stomach upsets including nausea, vomiting and diarrhoea, constipation
Estonian: iiveldus, oksendamine ja kõhulahtisus, kõhukinnisus
English: TAXOTERE 80 mg/4 ml concentrate for solution for infusion docetaxel
Estonian: TAXOTERE 80 mg/4 ml infusioonilahuse kontsentraat Docetaxelum
English: Dyspnoea (G3/4: 1%); Cough (G3/4: < 1%);
Estonian: aste: 1%); Köha (3./4.
English: Tabulated list of adverse reactions in breast cancer for TAXOTERE 100 mg/m² in combination with trastuzumab
Estonian: Kõrvaltoimete tabel rinnanäärmevähi kombinatsioonravi korral TAXOTERE-ga annuses 100 mg/m2 ja trastuzumabiga
English: TAXOTERE in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.
Estonian: TAXOTERE kombinatsioonis kapetsitabiiniga on näidustatud lokaalselt levinud või metastaatilise rinnanäärmevähi raviks patsientidel, kellel eelnev tsütotoksiline ravi on ebaõnnestunud.
English: TAXOTERE monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.
Estonian: TAXOTERE on näidustatud lokaalselt levinud või metastaatilise rinnanäärmevähi monoteraapiaks patsientidel, kellel eelnev tsütotoksiline ravi on ebaõnnestunud.
English: Tabulated list of adverse reactions in breast cancer for TAXOTERE 100 mg/m² single agent
Estonian: Kõrvaltoimete tabel rinnanäärmevähi monoteraapia korral TAXOTERE-ga annuses 100 mg/m2
English: TAXOTERE in combination with platinum agents in chemotherapy-naïve patients
Estonian: TAXOTERE ja plaatinapreparaatide kombinatsioon varem keemiaravi mittesaanud patsientidel
English: The concentrate is supplied in a 7 ml clear colourless glass vial with a magenta aluminium seal and a magenta plastic flip-off cap.
Estonian: Kontsentraat on saadaval 7 ml läbipaistvast, värvitust klaasist viaalis, millel on punakas-roosa alumiiniumist sulgur ja punakasvioletne plastikust rebitav kate.
English: Abdominal pain (severe: 1%);
Estonian: Asteenia (tõsine: Vedelikupeetus (tõsine: 1,2%); Valu
English: The addition of the entire contents of the solvent vial to the contents of the TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
Estonian: Kogu lahusti koguse lisamine TAXOTERE 20 mg/0,5 ml infusioonilahuse kontsentraadi viaali sisule tagab eellahuses dotsetakseeli kontsentratsiooni 10 mg/ml.
English: What TAXOTERE looks like and contents of the pack TAXOTERE 80 mg/2 ml concentrate for solution for infusion is a clear viscous, yellow to brownyellow solution.
Estonian: TAXOTERE 80 mg/2 ml infusioonilahuse kontsentraat on läbipaistev viskoosne kollane kuni pruunikaskollane lahus.
English: The addition of the entire contents of the solvent vial to the contents of the TAXOTERE 80 mg/2 ml vial ensures a premix concentration of 10 mg/ml docetaxel.
Estonian: Kogu lahustiviaali sisu lisamine TAXOTERE 80 mg/2 ml viaalile tagab eellahuses dotsetakseeli kontsentratsiooniga 10 mg/ml.
English: For cisplatin dose adjustments, see the corresponding summary of product characteristics.
Estonian: Trastuzumabi annuse kohandamise kohta informatsiooni saamiseks lugege trastuzumabi ravimi omaduste kokkuvõtet.
English: In GEICAM 9805 study alopecia that started during the treatment period and persisted into the followup period was observed to be ongoing in 49 patients (9.2 %) in TAC arm and 35 patients (6.7 %) in FAC arm. Alopecia related to study drug started or worsened during the follow-up period in 42 patients (7.9 %) in TAC arm and 30 patients (5.8 %) in FAC arm. At the end of the follow-up period (median follow-up time of 10 years and 5 months), alopecia was observed to be ongoing in 3 patients (0.6%) in TAC arm, and in 1 patient (0.2%) in FAC arm.
Estonian: Uuringus GEICAM 9805 täheldati kestvat alopeetsiat, mis algas raviperioodil ning püsis jälgimisperioodil, 49 patsiendil (9,2%) TAC ravihaaras ja 35 patsiendil (6,7%) FAC ravihaaras.
English: If TAXOTERE concentrate, premix solution or infusion solution should come into contact with skin, wash immediately and thoroughly with soap and water.
Estonian: Kui TAXOTERE kontsentraat, eellahus või infusioonilahus satub nahale, tuleb see viivitamatult ning hoolikalt seebi ja veega maha pesta.
English: Vomiting (G3/4:
Estonian: Oksendamine (3./4.
English: Median (months) 95% CI
Estonian: Elulemuse mediaan (kuud) 95% CI
English: TAXOTERE 160 mg/8 ml concentrate for solution for infusion.
Estonian: TAXOTERE 160 mg/8 ml infusioonilahuse kontsentraat
English: Rare (may affect up to 1 in 1,000 people):
Estonian: Harv (võib tekkida kuni 1 inimesel 1000-st):
English: TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion docetaxel
Estonian: TAXOTERE 20 mg/0,5 ml kontsentraat ja lahusti infusioonilahuse jaoks Docetaxelum
English: ** PSA response: Prostate-Specific Antigen response: PSA level <0.2 ng/mL measured for two consecutive measurements at least 4 weeks apart.
Estonian: 95% CI p-väärtusa* a juhuni kulunud aja muutujad; kihitatud logaritmiline astaktest; ravivastuse määra muutujad: Fisheri täpsustest *p-väärtus kirjeldaval eesmärgil *** PSA ravivastus - prostata-spetsiifilise antigeeni ravivastus: PSA sisaldus <0,2 ng/ml kahe järjestikuse mõõtetulemusena vähemalt 4-nädalase vahega.
English: Stomatitis (G3/4: 1.7%); Vomiting (G3/4: 0.8%); Diarrhoea (G3/4: 1.7%)
Estonian: aste: 1,7%); Oksendamine (3./4.
English: Excipients
Estonian: SPETSIFIKATSIOON
English: The addition of the entire contents of the solvent vial to the contents of the TAXOTERE 80 mg/2 ml concentrate for solution for infusion vial ensures a premix concentration of 10 mg/ml docetaxel.
Estonian: Kogu lahusti koguse lisamine TAXOTERE 80 mg/2 ml infusioonilahuse kontsentraadi viaali sisule tagab eellahuses dotsetakseeli kontsentratsiooni 10 mg/ml.
English: For trastuzumab dose modifications, see trastuzumab summary of product characteristics.
Estonian: Trastuzumabi annustamise ja manustamise kohta informatsiooni saamiseks lugege trastuzumabi ravimi omaduste kokkuvõtet.
English: Docetaxel in combination with trastuzumab was studied for the treatment of patients with metastatic breast cancer whose tumours over express HER2, and who previously had not received chemotherapy for metastatic disease.
Estonian: Dotsetakseeli ja trastuzumabi kombinatsioonravi uuriti varasemalt keemiaravi mittesaanud HER2 üleekspressiooniga metastaatilise rinnanäärmevähiga patsientidel.
English: • muscle aches and pains; back pain or bone pain
Estonian: • lihaste valu või valulikkus, seljavalu või luuvalu
English: Description of selected adverse reactions in gastric adenocarcinoma cancer for TAXOTERE 75 mg/m2 in combination with cisplatin and 5-fluorouracil
Estonian: Kõrvaltoimete valikuline kirjeldus mao adenokartsinoomi kombinatsioonravi korral TAXOTERE-ga annuses 75 mg/m2 ning tsisplatiini ja 5-fluorouratsiiliga
English: Tabulated list of adverse reactions in head and neck cancer for TAXOTERE 75 mg/m² in combination with cisplatin and 5-fluorouracil
Estonian: Kõrvaltoimete tabel pea- ja kaelapiirkonna vähi kombinatsioonravi korral TAXOTERE-ga annuses 75 mg/m2 ning tsisplatiini ja 5-fluorouratsiiliga
English: Aseptically withdraw the required amount of TAXOTERE concentrate for solution for infusion using a calibrated syringe fitted with a 21G needle.
Estonian: Tõmmake aseptiliselt vajalik kogus TAXOTERE infusioonilahuse kontsentraati kalibreeritud süstlasse.
English: Tabulated list of adverse reactions in breast cancer for TAXOTERE 75 mg/m² in combination with capecitabine
Estonian: Kõrvaltoimete tabel rinnanäärmevähi kombinatsioonravi korral TAXOTERE-ga annuses 75 mg/m2 ja kapetsitabiiniga
English: Patients on the comparator arm received cisplatin (P) 100 mg/m followed by 5-fluorouracil (F)
Estonian: Võrdlushaara patsiendid said tsisplatiini (P) 100 mg/m2 ja seejärel 5-fluorouratsiili (F) 1000 mg/m2 päevas 5 päeva (PF).
English: If TAXOTERE concentrate or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water.
Estonian: Kui TAXOTERE kontsentraat või infusioonilahus peaks sattuma limaskestadele, tuleb see viivitamatult ja hoolikalt veega maha pesta.
English: Thrombocytopenia (G4: 1.7%)
Estonian: sepsis ja pneumoonia, fataalne 1,7%)
English: PREPARATION GUIDE FOR USE WITH TAXOTERE 160 mg/8 ml CONCENTRATE FOR SOLUTION FOR INFUSION
Estonian: Pakendi infoleht: teave kasutajale TAXOTERE 160 mg/8 ml kontsentraat ja lahusti infusioonilahuse jaoks dotsetakseel
English: Neutropenia (G3/4: 32%); Anaemia (G3/4: 4.9%)
Estonian: aste: 20,9%); Neutropeenia (3./4.
English: Peripheral sensory neuropathy (G3/4: 0.8%)
Estonian: Febriilne neutropeenia Trombotsütopeenia (4. aste: 0,8%)
English: Ventricular arrhythmia including ventricular tachycardia (frequency not known), sometimes fatal, has been reported in patients treated with docetaxel in combination regimens including doxorubicin, 5fluorouracil and/ or cyclophosphamide.
Estonian: Patsientidel, keda on ravitud dotsetakseeliga osana kombinatsioonravist, mis sisaldab doksorubitsiini, 5-fluorouratsiili ja/või tsüklofosfamiidi, on teatatud ventrikulaarsest arütmiast, k.a ventrikulaarsest tahhükardiast (sagedus teadmata), mis mõnikord on lõppenud surmaga.
English: PREPARATION GUIDE FOR USE WITH TAXOTERE 20 mg/1 ml CONCENTRATE FOR SOLUTION FOR INFUSION
Estonian: Pakendi infoleht: teave kasutajale TAXOTERE 20 mg/1 ml infusioonilahuse kontsentraat dotsetakseel
English: Description of selected adverse reactions in breast cancer for Taxotere 100 mg/m in combination with trastuzumab
Estonian: Rinnanäärmevähi kõrvaltoimete valikuline kirjeldus TAXOTERE-ga annuses 100 mg/m2 ja trastuzumabiga
English: • nasal drainage; inflammation of the throat and nose; cough
Estonian: • voolus ninast, kurgu ja nina põletik, köha
English: Dysgeusia (G3/4: < 1%); Pareaesthesia (G3/4: < 1%)
Estonian: Alopeetsia (3. aste: 3%)a Küünte muutused (3. aste: 1%)
English: Each box contains one vial.
Estonian: Üks viaal karbis.
English: Neutropenic infection; Infection (G3/4: 11.7%)
Estonian: Infektsioonid ja infestatsioonid Infektsioon (3./4.
English: TAXOTERE 80 mg/2 ml concentrate and solvent for solution for infusion
Estonian: TAXOTERE 80 mg/2 ml infusioonilahuse kontsentraat ja lahusti
English: Median survival (months) 95% CI
Estonian: Keskmine elulemus (kuud) 95% CI
English: C-docetaxel has been conducted in three cancer patients.
Estonian: Kolmel vähipatsiendil on läbi viidud uuring 14C-dotsetakseeliga.
English: Skin exfoliative (G3/4:
Estonian: Naha eksfoliatsioon (3./4.
English: Neutropenia (G3/4: 83.2%); Thrombocytopenia (G3/4:
Estonian: aste: 10,8%); Trombotsütopeenia (4. aste:
English: Cancer pain (G3/4:
Estonian: Kasvaja valu (3./4.
English: TAXOTERE in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
Estonian: TAXOTERE kombinatsioonis tsisplatiini ja 5-fluorouratsiiliga on näidustatud mao metastaatilise adenokartsinoomi, k.a.
English: Diarrhoea (G3/4: 6.2%); Vomiting (G3/4: 5%); Constipation
Estonian: aste: 6%); Oksendamine (3./4.
English: TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion
Estonian: TAXOTERE 20 mg/0,5 ml infusioonilahuse kontsentraat ja lahusti
English: PSA response** at 6 months - N(%) p-valuea*
Estonian: PSA** ravivastus (%)
English: Description of selected adverse reactions in gastric adenocarcinoma cancer for TAXOTERE 75 mg/m in combination with cisplatin and 5-fluorouracil
Estonian: Kõrvaltoimete valikuline kirjeldus mao adenokartsinoomi kombinatsioonravi korral TAXOTERE-ga annuses 75 mg/ m² ning tsisplatiini ja 5-fluorouratsiiliga
English: Surgery on the primary site of disease and/or neck could be considered at any time following completion of CRT.
Estonian: Haiguse algkolde ja/või kaela kirurgilist resektsiooni võis teha igal ajal pärast KRT-d. Kõik dotsetakseeli sisaldava haara patsiendid said profülaktiliselt antibiootikume.
English: Infection (G3/4: 3.6%) Neutropenic infection
Estonian: Infektsioonid ja infestatsioonid Neutropeeniline infektsioon (3./4.
English: After 10 years of follow-up in GEICAM 9805 study, acute leukaemia occurred in 1 of 532 (0.2%) patients in TAC arm. No cases were reported in patients in FAC arm. No patient was diagnosed with myelodysplastic syndrome in either treatment groups.
Estonian: GEICAM uuringu 10-aastase jälgimisperioodi lõpuks tekkis äge leukeemia 1 patsiendil 532-st (0,2%) TAC ravihaaras.
English: Median overall survival (months) (95% CI)
Estonian: Elulemuse mediaan (kuudes) (95% CI)
English: Dizziness (G3/4:
Estonian: Düsgeusia (3./4.
English: PREPARATION GUIDE FOR USE WITH TAXOTERE 80 mg/4 ml CONCENTRATE FOR SOLUTION FOR INFUSION
Estonian: Pakendi infoleht: teave kasutajale TAXOTERE 80 mg/4 ml infusioonilahuse kontsentraat dotsetakseel
English: If TAXOTERE concentrate, premix solution or infusion solution should come into contact with mucous membranes, wash immediately and thoroughly with water.
Estonian: Kui TAXOTERE kontsentraat, eellahus või infusioonilahus satub limaskestadele, tuleb see viivitamatult ja hoolikalt veega maha pesta.
English: Infection (G3/4: 7.8%)
Estonian: aste: 8,7%)
English: TAXOTERE 80 mg/2 ml concentrate and solvent for solution for infusion docetaxel
Estonian: TAXOTERE 80 mg/2 ml kontsentraat ja lahusti infusioonilahuse jaoks Docetaxelum
English: Anaemia (G3/4: 3%); Neutropenia (G3/4:
Estonian: Neutropeenia (4. aste: Aneemia (3./4.
English: Dysgeusia/Parosmia (G3/4: 0.4%);
Estonian: aste: Trombotsütopeenia (4. aste: 0,5%)
English: TAXOTERE 20 mg/0.5 ml concentrate for solution for infusion vial
Estonian: TAXOTERE 20 mg/0,5 ml infusioonilahuse kontsentraat viaalis:
English: Weight increased (G3/4:
Estonian: Suurenenud pisaraeritus (3./4.
English: Cisplatin
Estonian: Vedelikupeetus